PAM抗体;PAM Antibody—艾普蒂

+ +

•  

   

     Western blot analysis using PAM mouse mAb against  U-251MG lysate    

  
  

•  

   

     IHC-P analysis of heart muscle tissue by PAM antibody (P15411) IHC-P was performed using sections of the formalin-fixed paraffin-embedded heart muscle tissue;Result: Cardiomyocytes are positively stained at the cytoplasm.    

  
  

**Background of PAM Antibodies**

PAM (anti-aminoacyl-tRNA synthetase) antibodies are a group of autoantibodies targeting aminoacyl-tRNA synthetases, enzymes essential for protein synthesis by attaching amino acids to their corresponding tRNA molecules. These antibodies are strongly associated with idiopathic inflammatory myopathies (IIM), particularly polymyositis and dermatomyositis, and are a hallmark of antisynthetase syndrome—a clinical condition characterized by myositis, interstitial lung disease, arthritis, Raynaud’s phenomenon, and mechanic’s hands.

First identified in the 1980s, the most common PAM antibody is anti-Jo-1 (targeting histidyl-tRNA synthetase), accounting for ~80% of cases. Other subtypes (e.g., anti-PL-7. anti-PL-12) target different synthetases and exhibit varying clinical associations. Their pathogenesis remains unclear but may involve molecular mimicry, environmental triggers (e.g., viral infections), or genetic predisposition (e.g., HLA-DR alleles).

PAM antibodies aid in diagnosis, prognosis, and subtyping of IIM. Patients with these antibodies often have aggressive interstitial lung disease, influencing treatment strategies. Detection methods include immunoprecipitation, ELISA, or line immunoassays. Despite their clinical utility, the direct role of these autoantibodies in tissue damage—whether pathogenic or bystanders—requires further study. Research continues to explore targeted therapies to modulate immune responses against synthetases.